Special Report: Are Nicotine Vaccines Poised to Expand Treatment Options and Market Size in Nicotine Addiction?

Only 4.6% of people addicted to nicotine received any prescription drug treatment in 2009, even in the world's major pharmaceutical markets. Very few effective medications are available to treat nicotine addiction, as reflected by the remarkably low diagnosis and drug-treatment rates for nicotine addiction. According to the psychiatrists surveyed by Decision Resources, the greatest unmet need in the current nicotine addiction market is for more treatments and more-effective treatments, particularly better anticraving medications. Given this large unmet need as well as the high prevalent population, this market is primed for competitive entry.

Questions Answered

• Pfizer dominates the current prescription therapy market for nicotine addiction. What is the outlook for Pfizer? Are any other companies developing therapies that have the potential to challenge Pfizer's position in the nicotine addiction market?
• Diagnosis and prescription drug rates for nicotine addiction are remarkably low, despite the high prevalence of nicotine addiction in the seven markets under study. What are the reasons for these low rates? How can they be improved? What are the market insights for drug developers in this space?
• Surveyed specialists treat smokers based on the extent of smokers' addiction, as well as other factors, but acknowledge the need for more, and different, treatment options. What is the preferred therapy for a heavy smoker versus a light smoker according to our survey results? What are the unmet needs in the current market according to our survey results?
• Smoking is a serious healthcare problem worldwide. What is the prevalent patient population in the seven major markets covered in this report? What percentage of that population is diagnosed and treated with prescription pharmaceuticals? How will the size of these populations change over our 2009-2019 epidemiology study period?
• Therapeutic nicotine vaccines represent a completely novel approach to the prevention and treatment of nicotine addiction. What is the status and outlook for these emerging therapies? How will they affect the overall nicotine addiction treatment marketplace? What other therapies are in the development pipeline?

Scope

• Markets covered: Major pharmaceutical markets: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
• Primary research: A July 2010 survey of 52 U.S. psychiatrists covering topics such as factors influencing choice of treatment, current first-line treatments, current second-line treatments, and emerging therapies for nicotine addiction.
• Epidemiology: Decision Resources epidemiology analysis and estimates of prevalent cases of nicotine addiction and percentage of diagnosed and drug-treated cases over a 2009-2019 study period.
• Emerging therapies: Phase I: 3 drugs; Phase II: 2 drugs; Phase III: 1 drug.
• Mechanisms of action: Nicotine replacement therapies, anticraving medications, nicotine vaccines, and combination therapies.
• Exhibits: 14 figures and 2 tables.
• Market: 2009 major-market sales, trends, strategic considerations for competitors.

Please note, the PDF e-mail from publisher version of this report is for a global site license.